Want to see AU:ANR full AI Analyst Report?
Top Page
Anatara Lifesciences Ltd
(Sydney:ANR)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:Reiterated
Date:08/20/26
The score is driven primarily by weak financial performance—ongoing losses, zero revenue in 2026, and continued negative operating/free cash flow—partially offset by a cleaner balance sheet with zero debt and positive equity. Technical indicators also point to weak momentum (oversold RSI with slightly negative MACD), and valuation is constrained by a negative P/E and lack of dividend yield.
Positive Factors
Debt-Free Balance Sheet
Zero debt reduces mandatory financing costs and near-term leverage risk, while positive equity provides a stronger capital base. This gives Anatara greater flexibility to fund development or pursue partnerships, although continued losses could reduce that cushion.
Negative Factors
Revenue Deterioration
The loss of reported revenue leaves no established top-line base to support ongoing operations or validate commercial traction. Rebuilding consistent sales will be essential before Anatara can demonstrate recurring demand, operating leverage, or meaningful scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
Zero debt reduces mandatory financing costs and near-term leverage risk, while positive equity provides a stronger capital base. This gives Anatara greater flexibility to fund development or pursue partnerships, although continued losses could reduce that cushion.
Read all positive factors
Anatara Lifesciences Ltd (ANR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.85M
Dividend YieldN/A
Average Volume (3M)59.97K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue GrowthN/A
EPS Growth64.58%
CountryAU
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding316,310,400
10 Day Avg. Volume50,098
30 Day Avg. Volume59,972
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.91
Price to Sales (P/S)0.00
P/FCF Ratio-8.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Anatara Lifesciences Ltd Business Overview & Revenue Model
Company Description
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastroi...
How the Company Makes Money
null...
Anatara Lifesciences Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 969.46K | 644.03K | 0.00 | 0.00 |
| Gross Profit | -84.00 | -633.97K | -748.91K | -24.76K | -24.68K |
| EBITDA | -1.25M | -1.96M | -1.46M | -3.21M | -2.97M |
| Net Income | -933.23K | -1.95M | -1.45M | -2.02M | -2.53M |
Balance Sheet | |||||
| Total Assets | 820.39K | 1.15M | 1.67M | 1.42M | 1.77M |
| Cash, Cash Equivalents and Short-Term Investments | 470.92K | 101.36K | 982.11K | 401.18K | 1.17M |
| Total Debt | 0.00 | 407.42K | 0.00 | 0.00 | 65.80K |
| Total Liabilities | 108.86K | 612.42K | 306.85K | 494.83K | 403.35K |
| Stockholders Equity | 711.54K | 535.97K | 1.36M | 924.54K | 1.36M |
Cash Flow | |||||
| Free Cash Flow | -339.24K | -2.27M | -1.25M | -2.26M | -2.24M |
| Operating Cash Flow | -339.24K | -2.27M | -1.25M | -2.26M | -2.23M |
| Investing Cash Flow | 0.00 | 0.00 | 50.00K | -1.73K | -56.56K |
| Financing Cash Flow | 708.80K | 1.39M | 1.83M | 1.49M | -22.44K |
Anatara Lifesciences Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | AU$83.22M | 22.67 | 46.74% | ― | 29.68% | 1520.00% | |
52 Neutral | AU$21.17M | -3.98 | -20.36% | 8.93% | -30.79% | -177.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$16.79M | -4.03 | -31.88% | ― | 5.85% | 42.92% | |
47 Neutral | AU$52.00M | -0.59 | -118.74% | ― | 499.47% | 31.20% | |
44 Neutral | AU$2.85M | -2.65 | -101.34% | ― | ― | 64.58% | |
43 Neutral | AU$108.55M | -6.85 | 84.67% | ― | ― | 42.51% |
* Healthcare Sector Average
AU:ANR
Anatara Lifesciences Ltd
0.01
-0.01
-50.00%
AU:IMC
Immuron Limited
0.05
-0.02
-27.78%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.11
-84.80%
AU:EZZ
EZZ Life Science Holdings Ltd.
0.45
-1.74
-79.46%
AU:BIO
Biome Australia Ltd
0.37
-0.10
-21.51%
AU:RCE
Recce Pharmaceuticals Ltd.
0.36
-0.05
-12.35%
Anatara Lifesciences Ltd Corporate Events
Anatara Lifesciences Narrows Annual Loss but Faces Going-Concern Warning
Aug 18, 2026
Anatara Lifesciences Ltd is a biotechnology company focused on developing therapeutic products, with its activities reflected through consolidated financial reporting for the group. The company operates without paying dividends, indicating an emph...
Anatara Advances Anti-Obesity Candidate AOC and GaRP IBS Program Amid Strategic Review
Jul 31, 2026
Anatara Lifesciences reported Q4 FY26 progress on its Anti-Obesity Project, where pre-clinical studies identified a candidate compound, AOC, showing statistically significant effects in attenuating post-semaglutide weight regain and reducing visce...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.